Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Technical Officer | February 01, 2018 | February 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 50,000 |
Reported balance
After 2018-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-01 · Grant · Acquired 50,000 · Balance 50,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 5,900 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,900 |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2018 Filed Feb 5, 2018 16:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002891 · doc4.xml · derivative · entry 2 Watler Peter K. · CIK 0001622139 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029151 · doc4.xml · nonDerivative · entry 1 Watler Peter K. · CIK 0001622139 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,900 Read SEC document |
| August 06, 2017 Filed Aug 8, 2017 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-17-019842 · doc4.xml · derivative · entry 1 Watler Peter K. · CIK 0001622139 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2027-08-06 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to (i) fifty percent (50%) of the total number of shares subject to the option after one year measured from August 1, 2017 (the "Vesting Commencement Date"), (ii) an additional twenty-five percent (25%) of the total number of shares subject to the option on the eighteen (18) month anniversary of the Vesting Commencement Date and (iii) an additional twenty-five percent (25%) of the total number of shares subject to the option on the two year anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.